PMID- 20882048
OWN - NLM
STAT- MEDLINE
DCOM- 20110209
LR  - 20220317
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 25
IP  - 1
DP  - 2011 Jan
TI  - Unrelated cord blood transplantation in adults with myelodysplasia or secondary 
      acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
PG  - 75-81
LID - 10.1038/leu.2010.219 [doi]
AB  - The aim of our study was to evaluate, through the Eurocord and European Group for 
      Blood and Marrow Transplantation (EBMT) registries, outcomes and risk factors for 
      outcomes in adult patients who underwent single or double unrelated cord blood 
      transplantation (UCBT) for myelodysplastic syndrome (MDS) or secondary acute 
      myeloblastic leukemia (sAML). A total of 180 adults with MDS (n=39) or sAML 
      (n=69) were analyzed. Risk factors for outcomes were analyzed using the Fine and 
      Gray method and the Cox model. Median age was 43 (18-72) years. In all, 77 
      patients (71%) received a single UCBT. Myeloablative conditioning regimen (MAC) 
      was given to 57 (53%) patients. Median numbers of nucleated and CD34(+) cells at 
      freezing were 3.6 x 10(7) and 1.1 x 10(5) kg. At 60 days, cumulative incidence of 
      neutrophil recovery was 78+/-4% and was independently associated with the number of 
      CD34(+) cells per kg (>1.1 x 10(5); P=0.005) and advanced disease status (blasts 
      <5% at time of UCBT, P=0.016). A 2-year non-relapse mortality (NRM) was 
      significantly higher after MAC (62 vs 34%; P=0.009). A 2-year 
      disease-free-survival (DFS) and overall survival (OS) were 30 and 34%, 
      respectively. In multivariate analysis, patients with high-risk disease (blasts 
      >5% and International Prognostic scoring system (IPSS) intermediate-2 or high in 
      MDS) had significant poorer DFS (hazard ratio (HR): 1.76; P=0.047). In spite of 
      high NRM, these data indicate that UCBT is an acceptable alternative option to 
      treat adults with high-risk MDS or sAML, without a suitable human leukocyte 
      antigen (HLA)-matched donor.
FAU - Robin, M
AU  - Robin M
AD  - Service d'hematologie-greffe, Hopital Saint-Louis, APHP, Paris, France. 
      marie.robin@sls.aphp.fr
FAU - Sanz, G F
AU  - Sanz GF
FAU - Ionescu, I
AU  - Ionescu I
FAU - Rio, B
AU  - Rio B
FAU - Sirvent, A
AU  - Sirvent A
FAU - Renaud, M
AU  - Renaud M
FAU - Carreras, E
AU  - Carreras E
FAU - Milpied, N
AU  - Milpied N
FAU - Mohty, M
AU  - Mohty M
FAU - Beguin, Y
AU  - Beguin Y
FAU - Bordigoni, P
AU  - Bordigoni P
FAU - de Witte, T
AU  - de Witte T
FAU - Picardi, A
AU  - Picardi A
FAU - Purtill, D
AU  - Purtill D
FAU - Gluckman, E
AU  - Gluckman E
FAU - Kroger, N
AU  - Kroger N
FAU - Rocha, V
AU  - Rocha V
LA  - eng
PT  - Journal Article
DEP - 20100930
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Cord Blood Stem Cell Transplantation
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/mortality/*therapy
MH  - Neoplasms, Second Primary/*therapy
MH  - Recurrence
EDAT- 2010/10/01 06:00
MHDA- 2011/02/10 06:00
CRDT- 2010/10/01 06:00
PHST- 2010/10/01 06:00 [entrez]
PHST- 2010/10/01 06:00 [pubmed]
PHST- 2011/02/10 06:00 [medline]
AID - leu2010219 [pii]
AID - 10.1038/leu.2010.219 [doi]
PST - ppublish
SO  - Leukemia. 2011 Jan;25(1):75-81. doi: 10.1038/leu.2010.219. Epub 2010 Sep 30.